ABNCoV2
ABNCoV2 is a vaccine candidate for the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus. It is being developed by the German biopharmaceutical company Abivax in collaboration with the British American Tobacco subsidiary, Kentucky BioProcessing.
Development[edit | edit source]
The development of ABNCoV2 began in early 2020, following the global outbreak of the COVID-19 pandemic. The vaccine utilizes a unique virus-like particle (VLP) technology, which mimics the structure of the SARS-CoV-2 virus to stimulate an immune response. This technology has been used in the development of other successful vaccines, such as the HPV vaccine and Hepatitis B vaccine.
Clinical Trials[edit | edit source]
ABNCoV2 has undergone several phases of clinical trials to assess its safety and efficacy. The initial Phase I clinical trial involved a small group of healthy volunteers and focused on assessing the safety of the vaccine and the immune response it generates. The subsequent Phase II clinical trial and Phase III clinical trial involved larger groups of participants and aimed to further assess the vaccine's safety, efficacy, and optimal dosage.
Efficacy[edit | edit source]
While the final results of the clinical trials are yet to be published, preliminary data suggests that ABNCoV2 is effective in preventing COVID-19. The vaccine has been shown to generate a strong immune response, with high levels of antibodies and T cells detected in vaccinated individuals.
Side Effects[edit | edit source]
As with all vaccines, ABNCoV2 may cause side effects. Common side effects reported in the clinical trials include pain at the injection site, fatigue, headache, muscle pain, and fever. These side effects are typically mild and resolve on their own within a few days.
Distribution and Administration[edit | edit source]
Upon receiving regulatory approval, ABNCoV2 will be distributed globally. The vaccine is administered as an injection into the muscle, typically in the upper arm. As with other COVID-19 vaccines, two doses of ABNCoV2 are recommended for optimal protection.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
